Inactive Instrument

Press Releases Vital Therapies Inc Nasdaq

Equities

US92847R1041

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Immunic to Host MS R&D Day and Participate in Investor Conferences in April	Apr. 04	PR
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month	Mar. 21	AQ
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy	Mar. 21	AQ
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States	Mar. 20	PR
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024	Mar. 08	AQ
Immunic to Participate in Investor and Scientific Conferences in March	Mar. 07	PR
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024	Feb. 29	PR
Immunic reports successful 2023 and prepares for key 2025 milestones	Feb. 22	AQ
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update	Feb. 22	PR
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update	Feb. 15	PR
Immunic to Participate in Investor and Scientific Conferences in February	Feb. 01	PR
Immunic, Inc. Announces Private Placement of up to $240 Million	Jan. 05	PR
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis	Nov. 21	PR
Immunic focusing on business development during Q4	Nov. 14	AQ
Immunic: Q3 Earnings Snapshot	Nov. 14	AQ
Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 14	PR
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update	Nov. 07	PR
Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts	Nov. 02	PR
Immunic to Participate in Scientific and Industry Conferences in November	23-10-26	PR
Immunic CSO hails "great" progress with MS program	23-10-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vital Therapies Inc Nasdaq

Equities

US92847R1041

Press Releases

Filters